Skip to main content
. Author manuscript; available in PMC: 2017 Oct 12.
Published in final edited form as: Ann Surg Oncol. 2016 Feb 4;23(6):1993–2000. doi: 10.1245/s10434-016-5116-4

FIG. 2.

FIG. 2

Blocking the RAS-RAF-MEK-ERK signaling pathway results in significant inhibition of PDAC growth in the liver and prolongs survival of mice harboring hepatic PDAC. Mice received either the MEK inhibitor trametinib (0.3 mg/kg, oral gavage, daily) or vehicle control beginning 48 h post-splenic injection. a Representative images of hepatic bioluminescence from mice harboring Tumor 608 over the course of therapy (quantified linearly in b). Daily trametinib beginning 48 h post-splenic injection significantly decreased hepatic tumor burden (a) and prolonged time to proliferative outgrowth for both Tumor 608 (b) and Tumor 366 (c). Moreover, trametinib significantly prolonged survival of mice harboring hepatic Tumor 608 (d) and Tumor 366 (e)